Stock listing
NSE:BETA Beta Drugs Ltd. Share Price
Follow Beta Drugs Ltd. into a list and get an email when it puts out news.
Share price · NSE:BETA
₹1,655.40 INR -146.90 (-8.2%)
Close on Nov 20, 2026
- Day range
- ₹1,620.00 – ₹1,774.20 INRNov 20, 2026
- Volume
- 126,295 sharesNov 20, 2026
- Market cap
- ₹16.78B INRAt the close on Nov 20, 2026 · price × 10.14M shares outstanding
- 52-week range
- ₹990.10 – ₹2,807.90 INRLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₹82.53M INRMedian day 19,531 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NSE:BETA · INR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₹1,655.40 | -146.90 | -8.2% | ₹1,735.50 | ₹1,774.20 | ₹1,620.00 | 126,295 | |
| ₹1,802.30 | +9.80 | +0.5% | ₹1,792.50 | ₹1,841.50 | ₹1,765.80 | 16,700 | |
| ₹1,792.50 | -23.70 | -1.3% | ₹1,736.00 | ₹1,828.30 | ₹1,689.10 | 72,947 | |
| ₹1,816.20 | -1.20 | -0.1% | ₹1,830.70 | ₹1,858.00 | ₹1,771.20 | 17,094 | |
| ₹1,817.40 | -21.10 | -1.1% | ₹1,874.90 | ₹1,890.70 | ₹1,810.50 | 11,610 | |
| ₹1,838.50 | -32.50 | -1.7% | ₹1,891.40 | ₹1,891.80 | ₹1,806.10 | 15,840 | |
| ₹1,871.00 | -10.60 | -0.6% | ₹1,900.00 | ₹1,902.00 | ₹1,850.80 | 13,072 | |
| ₹1,881.60 | +75.70 | +4.2% | ₹1,834.10 | ₹1,925.90 | ₹1,820.60 | 22,889 | |
| ₹1,805.90 | -34.80 | -1.9% | ₹1,849.90 | ₹1,849.90 | ₹1,770.60 | 15,899 | |
| ₹1,840.70 | +71.10 | +4.0% | ₹1,817.40 | ₹1,847.00 | ₹1,800.20 | 19,489 | |
| ₹1,769.60 | +49.10 | +2.9% | ₹1,720.00 | ₹1,790.30 | ₹1,710.40 | 19,573 | |
| ₹1,720.50 | -54.60 | -3.1% | ₹1,796.50 | ₹1,845.90 | ₹1,695.10 | 24,491 | |
| ₹1,775.10 | -23.30 | -1.3% | ₹1,781.00 | ₹1,790.00 | ₹1,750.20 | 12,136 | |
| ₹1,798.40 | -51.30 | -2.8% | ₹1,880.60 | ₹1,880.60 | ₹1,790.60 | 23,660 | |
| ₹1,849.70 | -127.10 | -6.4% | ₹1,976.80 | ₹2,020.00 | ₹1,822.80 | 45,819 | |
| ₹1,976.80 | +42.60 | +2.2% | ₹1,955.00 | ₹2,099.60 | ₹1,903.80 | 70,040 | |
| ₹1,934.20 | -43.70 | -2.2% | ₹1,977.90 | ₹2,028.00 | ₹1,862.10 | 60,453 | |
| ₹1,977.90 | +83.30 | +4.4% | ₹1,896.00 | ₹2,035.00 | ₹1,895.20 | 75,889 | |
| ₹1,894.60 | -77.30 | -3.9% | ₹1,973.00 | ₹1,973.00 | ₹1,823.00 | 155,586 | |
| ₹1,971.90 | +292.90 | +17.4% | ₹1,664.70 | ₹1,997.60 | ₹1,616.00 | 567,442 | |
| ₹1,679.00 | -57.30 | -3.3% | ₹1,701.10 | ₹1,710.00 | ₹1,629.00 | 24,978 | |
| ₹1,736.30 | -53.70 | -3.0% | ₹1,779.80 | ₹1,779.80 | ₹1,700.00 | 18,555 | |
| ₹1,790.00 | +35.00 | +2.0% | ₹1,786.00 | ₹1,804.90 | ₹1,713.50 | 26,526 | |
| ₹1,755.00 | +55.50 | +3.3% | ₹1,700.00 | ₹1,870.00 | ₹1,674.20 | 161,207 | |
| ₹1,699.50 | +5.20 | +0.3% | ₹1,686.00 | ₹1,718.90 | ₹1,625.00 | 56,677 | |
| ₹1,694.30 | -151.20 | -8.2% | ₹1,845.00 | ₹1,859.40 | ₹1,660.00 | 125,336 | |
| ₹1,845.50 | -99.50 | -5.1% | ₹1,950.00 | ₹1,974.90 | ₹1,835.00 | 53,166 | |
| ₹1,945.00 | +25.00 | +1.3% | ₹1,910.00 | ₹1,974.00 | ₹1,703.10 | 158,957 | |
| ₹1,920.00 | -61.10 | -3.1% | ₹2,000.00 | ₹2,000.00 | ₹1,890.00 | 24,558 | |
| ₹1,981.10 | -19.00 | -0.9% | ₹1,980.00 | ₹2,024.00 | ₹1,980.00 | 9,114 | |
| ₹2,000.10 | -19.90 | -1.0% | ₹1,990.10 | ₹2,027.50 | ₹1,989.90 | 10,362 | |
| ₹2,020.00 | -35.00 | -1.7% | ₹2,064.50 | ₹2,173.80 | ₹1,986.70 | 19,642 | |
| ₹2,055.00 | +5.00 | +0.2% | ₹2,030.00 | ₹2,088.50 | ₹2,020.00 | 8,698 | |
| ₹2,050.00 | -34.80 | -1.7% | ₹2,079.90 | ₹2,095.00 | ₹2,026.60 | 7,218 | |
| ₹2,084.80 | +54.70 | +2.7% | ₹2,040.00 | ₹2,084.80 | ₹2,010.50 | 12,014 | |
| ₹2,030.10 | -69.90 | -3.3% | ₹2,080.00 | ₹2,100.00 | ₹2,020.00 | 12,981 | |
| ₹2,100.00 | -10.00 | -0.5% | ₹2,093.40 | ₹2,117.90 | ₹2,065.70 | 10,464 | |
| ₹2,110.00 | -78.00 | -3.6% | ₹2,190.50 | ₹2,197.90 | ₹2,080.00 | 16,148 | |
| ₹2,188.00 | +79.50 | +3.8% | ₹2,121.00 | ₹2,233.90 | ₹2,105.00 | 29,966 | |
| ₹2,108.50 | +29.50 | +1.4% | ₹2,080.00 | ₹2,170.00 | ₹2,063.40 | 20,315 | |
| ₹2,079.00 | +14.00 | +0.7% | ₹2,053.00 | ₹2,089.80 | ₹2,033.90 | 10,479 | |
| ₹2,065.00 | -30.00 | -1.4% | ₹2,095.20 | ₹2,147.90 | ₹2,025.00 | 14,462 | |
| ₹2,095.00 | +35.90 | +1.7% | ₹2,054.60 | ₹2,112.40 | ₹2,054.60 | 12,237 | |
| ₹2,059.10 | -59.90 | -2.8% | ₹2,082.20 | ₹2,094.70 | ₹2,002.60 | 13,984 | |
| ₹2,119.00 | -11.00 | -0.5% | ₹2,101.00 | ₹2,214.90 | ₹2,079.10 | 34,753 | |
| ₹2,130.00 | +44.00 | +2.1% | ₹2,070.00 | ₹2,147.80 | ₹2,013.80 | 18,068 | |
| ₹2,086.00 | -24.00 | -1.1% | ₹2,101.00 | ₹2,107.50 | ₹2,073.00 | 11,535 | |
| ₹2,110.00 | -25.00 | -1.2% | ₹2,150.50 | ₹2,163.90 | ₹2,105.00 | 9,360 | |
| ₹2,135.00 | -24.00 | -1.1% | ₹2,115.00 | ₹2,173.90 | ₹2,115.00 | 13,277 | |
| ₹2,159.00 | -52.00 | -2.4% | ₹2,204.00 | ₹2,204.00 | ₹2,087.90 | 42,831 | |
| ₹2,211.00 | -69.00 | -3.0% | ₹2,258.00 | ₹2,275.70 | ₹2,190.10 | 13,251 | |
| ₹2,280.00 | +80.00 | +3.6% | ₹2,145.00 | ₹2,285.00 | ₹2,145.00 | 27,003 | |
| ₹2,200.00 | -19.80 | -0.9% | ₹2,208.50 | ₹2,208.50 | ₹2,076.00 | 44,647 | |
| ₹2,219.80 | -58.20 | -2.6% | ₹2,277.00 | ₹2,277.00 | ₹2,180.00 | 12,964 | |
| ₹2,278.00 | +82.90 | +3.8% | ₹2,190.00 | ₹2,371.80 | ₹2,153.00 | 29,195 | |
| ₹2,195.10 | -5.90 | -0.3% | ₹2,194.20 | ₹2,253.00 | ₹2,166.20 | 16,090 | |
| ₹2,201.00 | -59.00 | -2.6% | ₹2,261.00 | ₹2,293.30 | ₹2,179.30 | 26,249 | |
| ₹2,260.00 | -37.50 | -1.6% | ₹2,370.00 | ₹2,387.00 | ₹2,255.00 | 18,297 | |
| ₹2,297.50 | +1.50 | +0.1% | ₹2,307.00 | ₹2,319.50 | ₹2,251.00 | 9,982 | |
| ₹2,296.00 | -40.80 | -1.7% | ₹2,300.10 | ₹2,400.00 | ₹2,289.10 | 20,970 | |
| ₹2,336.80 | +31.80 | +1.4% | ₹2,285.00 | ₹2,354.10 | ₹2,258.30 | 18,277 | |
| ₹2,305.00 | -103.00 | -4.3% | ₹2,446.00 | ₹2,446.00 | ₹2,270.00 | 34,219 |
Splits
1 split · NSE:BETA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 21-for-20 | Split |
- Ticker
- NSE:BETA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- NSE
- Currency
- INR
What changed lately
Latest news release · Nov 19, 2026
Beta Drugs Limited has informed the Exchange regarding a press release dated November 19, 2026, titled "Beta Drugs Limited (Beta) forms Oncology Joint Venture withIMGSA Groupe SPA (IMGSA)".
Latest deck · Oct 22, 2026
H1 FY27 Earnings Presentation
Earnings · 23 slides
Latest news
Beta Drugs Limited has informed the Exchange regarding a press release dated November 19, 2026, titled "Beta Drugs Limited (Beta) forms Oncology Joint Venture withIMGSA Groupe SPA (IMGSA)".
Nov 19, 2026
Closed ₹1,655.40 (-8.2%) on Nov 20, 2026
Beta Drugs Achieves Regulatory Milestones In Azerbaijan And Philippines
Apr 21, 2026
Closed ₹1,313.00 (-1.4%) on Apr 22, 2026
Beta Drugs To Buy 66.09% Of Nivian Life Sciences For 694 MLN Rupees
Jan 9, 2026
Closed ₹1,590.00 (+1.0%) on Jan 12, 2026
Beta Drugs Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 4 in the last 12 months · 5 in all · newest Nov 19, 2026 · oldest 2025
- Decks
- 13 decks · latest Oct 22, 2026
Valuation
P/E 36.8× against a median of 23.3×: 6th lowest of 9 Pharmaceuticals companies shown. Statements: 4 quarters to Jun 30, 2026 · balance Mar 31, 2026 · price Nov 20, 2026
- Enterprise value
- ₹16.71B INR
- P/E
- 36.8×
- EV/sales
- 4.1×
- EV/EBITDA
- 20.1×
- Price/book
- 6.9×
- Gross margin
- 51.0%
- Operating margin
- 16.0%
- Net margin
- 11.1%
- Debt to equity
- 0.5×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Beta Drugs Ltd. · NSE:BETA | US$181.1M | US$180.3M | 36.8× | 4.1× | 20.1× | 6.9× | 11.1% | 0.5× | n/a |
| Alpha Cognition Inc. · NASDAQ:ACOG | US$198.4M | US$160.6M | n/a | 8.0× | n/a | 4.0× | −144.6% | 0.0× | 0.85 |
| Jiangxi Institute of Biological Products Inc. Class H · HKEX:6915 | US$195.9M | US$184.8M | 13.8× | 5.2× | 10.2× | 2.6× | 40.3% | 0.0× | n/a |
| Ginwa Enterprise (Group) Inc. Class A · SSE:600080 | US$188.9M | US$148.9M | n/a | 1.9× | n/a | 0.8× | −10.3% | 0.0× | n/a |
| JW Holdings Corporation · KRX:096760 | US$187.0M | US$109.7M | 3.0× | 0.1× | 0.6× | 0.9× | 8.3% | 0.0× | n/a |
| NGL Fine-Chem Ltd. · NSE:NGLFINE | US$183.2M | US$183.2M | 29.7× | 3.2× | 20.2× | 5.2× | 10.7% | 0.0× | n/a |
| Sinphar Pharmaceutical Co. Ltd. · TWSE:1734 | US$179.9M | US$193.6M | 16.9× | 1.9× | 9.6× | 1.7× | 10.2% | 0.6× | n/a |
| Golden Throat Holdings Group Co Ltd · HKEX:6896 | US$177.8M | US$121.9M | 4.7× | 0.9× | 2.4× | 1.0× | 26.6% | 0.6× | n/a |
| CF PharmTech. Inc. Class H · HKEX:2652 | US$173.6M | US$114.7M | 466× | 1.8× | 12.4× | 0.9× | 0.6% | 0.1× | n/a |
| SIGA Technologies Inc. · NASDAQ:SIGA | US$172.5M | US$56.35M | 251× | 1.1× | n/a | 1.1× | 1.3% | 0.0× | 1.01 |
| Searle Company Ltd · PSX:SEARL | US$169.6M | US$163.7M | 68.6× | 1.2× | 6.4× | 1.4× | 1.8% | 0.0× | n/a |
| Median of the others | US$181.6M | US$154.7M | 23.3× | 1.8× | 9.6× | 1.2× | 5.1% | 0.0× | 0.93 |
Team and board
Officers
| Officer | Role |
|---|---|
| Nipun Arora | CHIEF FINANCIAL OFFICER (CFO) |
| Rajni Brar | COMPANY SECRETARY CUM COMPLIANCE OFFICER |
| Rahul Batra | CHAIRMAN AND MANAGING DIRECTOR |
| Varun Batra | JOINT MANAGING DIRECTOR |
Board
| Director | Role |
|---|---|
| Ashutosh Shukla | DIRECTOR |
| Balwant Singh | DIRECTOR |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 FY27 Earnings Presentation | Earnings | 23 slides | Oct 22, 2026 |
| Investor Presentation (July 2026) | Investor deck | 39 slides | Jul 27, 2026 |
| FY2026 Earnings Presentation | Earnings | 23 slides | May 15, 2026 |
| H1 FY2026 Earnings Presentation | Earnings | 23 slides | Nov 7, 2025 |
| Investor Presentation (May 2025) | Investor deck | 30 slides | May 15, 2025 |
| Investor Presentation (November 2024) | Investor deck | 30 slides | Nov 6, 2024 |
| Investor Presentation (May 2024) | Investor deck | 28 slides | May 14, 2024 |
| Investor Presentation (November 2023) | Investor deck | 24 slides | Nov 8, 2023 |
| Investor Presentation (May 2023) | Investor deck | 23 slides | May 8, 2023 |
| H1 2022-23 Earnings Presentation | Earnings | 22 slides | Oct 28, 2022 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (April 2022) | Investor deck | 20 slides | Apr 27, 2022 |
| Investor Presentation (December 2021) | Investor deck | 24 slides | Dec 3, 2021 |
| Investor Presentation (May 2021) | Investor deck | 21 slides | May 5, 2021 |
Financials
Annual, in INR
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 3.85B | 3.62B | 2.96B | 2.27B | 1.84B |
| Cost of revenue | 1.79B | 1.77B | 1.81B | 1.30B | 1.12B |
| Gross profit | 2.05B | 1.86B | 1.15B | 976.1M | 716.0M |
| Selling, general and administrative | 160.3M | 145.0M | 78.4M | 59.3M | 46.6M |
| Operating income | 585.3M | 620.9M | 501.3M | 430.3M | 354.5M |
| Depreciation and amortization | 171.5M | 125.1M | 97.8M | 104.1M | 72.5M |
| EBITDA | 756.8M | 746.1M | 599.2M | 534.4M | 427.0M |
| Interest expense | 150.2M | 67.4M | 26.8M | 22.8M | 17.9M |
| Income before tax | 543.9M | 569.7M | 487.5M | 410.6M | 343.0M |
| Net income | 414.8M | 424.2M | 364.4M | 307.2M | 248.3M |
| Earnings per share, basic | 40.92 | 42.02 | 36.10 | 30.43 | 24.60 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cash and equivalents | 1.25B | 1.47B | 286.3M | 191.6M | 173.2M |
| Short-term investments | 154.5M | ||||
| Receivables | 1.19B | 1.03B | 792.4M | 627.2M | 451.8M |
| Inventory | 744.6M | 597.7M | 498.1M | 306.2M | 224.8M |
| Current assets | 3.35B | 3.20B | 1.78B | 1.28B | 969.6M |
| Goodwill | 27.5M | 27.5M | 27.5M | 27.5M | 27.5M |
| Total assets | 4.96B | 4.36B | 2.54B | 1.98B | 1.58B |
| Accounts payable | 806.3M | 712.8M | 592.7M | 402.4M | 319.5M |
| Current liabilities | 1.08B | 1.03B | 846.7M | 630.2M | 489.7M |
| Long-term debt | 1.33B | 1.27B | 60.4M | 69.7M | 118.3M |
| Total liabilities | 2.51B | 2.39B | 969.8M | 755.4M | 655.1M |
| Shareholders' equity | 2.45B | 1.97B | 1.57B | 1.23B | 923.4M |
| Shares outstanding | 10.1M | 10.1M | 10.1M | 10.1M | 10.1M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cash from operations | 372.9M | 361.4M | 309.3M | 233.8M | 296.3M |
| Capital spending | -534.8M | -368.6M | -116.2M | -182.1M | -194.3M |
| Free cash flow | -162.0M | -7.14M | 193.1M | 51.7M | 102.0M |
| Change in cash | -221.8M | 1.18B | 94.7M | 18.4M | 69.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Beta Drugs Limited has informed the Exchange regarding a press release dated November 19, 2026, titled "Beta Drugs Limited ( Beta ) forms Oncology Joint Venture withIMGSA Groupe SPA ( IMGSA )". | Nov 19, 2026 | Acquisition or disposal | NSE India |
Cap table
Built by 6ix from Beta Drugs Ltd.’s releases
- Common shares
- 10,136,890
- Fully diluted
- 10,136,890
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 10,136,890 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 10,136,890 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ashutosh Shukla | DIRECTOR · Since at least Nov 6, 2026 |
| Balwant Singh | DIRECTOR · Since at least Nov 6, 2026 |
| Nipun Arora | CHIEF FINANCIAL OFFICER (CFO) · Since at least Nov 6, 2026 |
| Rahul Batra | CHAIRMAN AND MANAGING DIRECTOR · Since at least Nov 6, 2026 |
| Rajni Brar | COMPANY SECRETARY CUM COMPLIANCE OFFICER · Since at least Nov 6, 2026 |
| Varun Batra | JOINT MANAGING DIRECTOR · Since at least Nov 6, 2026 |
Log in to ask 6ix AI your own questions about Beta Drugs Ltd.